CL2024002103A1 - Métodos para tratar amiloidosis al - Google Patents

Métodos para tratar amiloidosis al

Info

Publication number
CL2024002103A1
CL2024002103A1 CL2024002103A CL2024002103A CL2024002103A1 CL 2024002103 A1 CL2024002103 A1 CL 2024002103A1 CL 2024002103 A CL2024002103 A CL 2024002103A CL 2024002103 A CL2024002103 A CL 2024002103A CL 2024002103 A1 CL2024002103 A1 CL 2024002103A1
Authority
CL
Chile
Prior art keywords
methods
treating amyloidosis
amyloidosis
treating
patients
Prior art date
Application number
CL2024002103A
Other languages
English (en)
Inventor
Kinney Gene
Zago Wagner
Tripuraneni RADHIKA
KARP Carol
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of CL2024002103A1 publication Critical patent/CL2024002103A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formulaciones de anticuerpo y métodos útiles para el tratamiento de pacientes con amiloidosis AL.
CL2024002103A 2022-01-11 2024-07-11 Métodos para tratar amiloidosis al CL2024002103A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263298396P 2022-01-11 2022-01-11

Publications (1)

Publication Number Publication Date
CL2024002103A1 true CL2024002103A1 (es) 2024-12-20

Family

ID=87279663

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002103A CL2024002103A1 (es) 2022-01-11 2024-07-11 Métodos para tratar amiloidosis al

Country Status (13)

Country Link
US (1) US20250345418A1 (es)
EP (1) EP4463486A2 (es)
JP (1) JP2025502173A (es)
KR (1) KR20240133743A (es)
CN (1) CN118749002A (es)
AU (1) AU2023207665A1 (es)
CA (1) CA3248146A1 (es)
CL (1) CL2024002103A1 (es)
IL (1) IL314229A (es)
JO (2) JOP20240155A1 (es)
MX (1) MX2024008652A (es)
TW (1) TW202346335A (es)
WO (1) WO2023137342A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025170969A1 (en) * 2024-02-06 2025-08-14 Prothena Biosciences Limited Methods of treating al amyloidosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4582446A3 (en) * 2019-03-05 2025-08-13 Prothena Biosciences Limited Methods of treating al amyloidosis

Also Published As

Publication number Publication date
US20250345418A1 (en) 2025-11-13
TW202346335A (zh) 2023-12-01
CA3248146A1 (en) 2023-07-20
JOP20240156A1 (ar) 2023-07-20
CN118749002A (zh) 2024-10-08
JOP20240155A1 (ar) 2024-07-11
EP4463486A2 (en) 2024-11-20
IL314229A (en) 2024-09-01
MX2024008652A (es) 2024-08-20
WO2023137342A2 (en) 2023-07-20
WO2023137342A3 (en) 2023-09-07
AU2023207665A1 (en) 2024-07-25
JP2025502173A (ja) 2025-01-24
KR20240133743A (ko) 2024-09-04

Similar Documents

Publication Publication Date Title
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
CL2021001201A1 (es) Métodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn
MX2023009681A (es) Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon.
CO2022000481A2 (es) Inhibidores de enzimas
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
ZA202103975B (en) Methods of treating disease with magl inhibitors
MX2024009153A (es) Metodos para el tratamiento de sujetos con psoriasis en placas del cuero cabelludo
EA202192288A1 (ru) Соединения на основе нейрегулина-4 и способы их применения
EA202190261A1 (ru) Топические маслянистые композиции
CO2022001354A2 (es) Métodos para tratar o prevenir la atrofia muscular espinal
CO2022000266A2 (es) Inhibidores de enzimas
CL2021000483A1 (es) Métodos y composiciones para el tratamiento de sujetos que padecen artritis reumatoide.
CO2022000270A2 (es) Inhibidores de enzimas
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
CO2022014199A2 (es) Composiciones de anticuerpo anti-cd6 y métodos para tratar y reducir efectos negativos de un coronavirus, incluyendo covid-19
CL2024002103A1 (es) Métodos para tratar amiloidosis al
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
MX2022014254A (es) Anticuerpos anti-hemojuvelina (hjv) para tratar mielofibrosis.
CO2025016192A2 (es) Moléculas y métodos de uso de estas
CL2023002236A1 (es) Métodos para tratar la amiloidosis primaria
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
BR112021019448A2 (pt) Métodos para o tratamento de beta-talassemia